##  [Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond Street, London NW3 2QG](/uk-en/about/partnerships/collaborative-working/royal-free-london-nhs-foundation-trust-nets-service "Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond Street, London NW3 2QG") 

 **Project Name:** Royal Free Neuroendocrine Tumours (NETs) Service Expansion

**Project Summary:**

This Collaborative Working Agreement (CWA) aims to recruit one FTE Neuro Endocrine Tumour (NETs) Fellow to support the collaboratove working (CW) partner with the co-ordination of the review, management, and treatment of patients within the NETs Service.

The recruitment of the NETs Fellow is part of a wider programme of works to expand the NETs Service within the Trust.

The expected outcomes of this Collaborative Working Project (CWP) are as follows.

- Increase in the number of NETS patients seen in the NETs Service
- Improvement in the time from decision to treat to first initiation
- Increased capacity to allow more treatments to be administered.
- Interval times between treatment more effectively monitored and adhered to.

The improved outcomes from the service expansion will enable a business case to be developed by the trust for permanent provision to ensure long term sustainability of the project.

**Planned Milestones:**

MilestoneDescription1**CW Partner and Novartis:** Kick-off meeting.2**CW Partner:** Confirmation of live advertisement for the recruitment of NETs Fellow.3**CW Partner:** Confirmation of interview dates for the recruitment of NETs Fellow.4**CW Partner:** Confirmation of recruitment of NETs Fellow.

**CW Partner:** Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity.

5**CW Partner:** Collection of **baseline data.**6-9**CW Partner:** Collection & Submission of clinical activity data every three months.

**CW Partner and Novartis:** Project review meeting to discuss project progress.

10**CW Partner:** Collection & submission of **Fifteen months clinical activity data**.

Initiation of development of Business Case.

**CW Partner and Novartis:** Project Review meeting to discuss project progress.

11-13**CW Partner:** Collection & submission of clinical activity data every three months.

**CW Partner and Novartis:** Project Review meeting to discuss project progress.

14**CW Partner:** Completion and submission of business case by the CW Partner team to relevant body within the NHS Board.15**CW Partner:** Submit final CWP report to Novartis within 2 months completion of the clinical work.**Expected Benefits:**

**ANTICIPATED BENEFITS FOR PATIENTS**

- *Reduction in time to treatment from a decision to treat.*
- *Improved disease awareness, treatment information and access to advanced NETs therapies*
- *Increased availability of hospital appointments required for therapy.*
- *Clinical support for patients related to therapy once initiated.*

**ANTICIPATED BENEFITS FOR THE ORGANISATION(S)**

- *Clinical and administrative support for a busy clinical service*
- *Ability to meet the needs of a wider cohort of patients who may be eligible for Advanced NETs Therapy, ensuring greater equity of access to innovative treatments.*
- *Improving the interface with referral centres*
- *Improved triaging across the region to meet demand.*
- *Improved capacity in NETS clinics*
- *Branding and reputational impact for the Trust*

**ANTICIPATED BENEFITS FOR NOVARTIS**

- *Increased access to Advanced NET therapies (which may include Novartis therapies)*
- *Reduction in geographical variation in therapy use*
- *Raised awareness of NETs treatments in the region*
- *Increased reputation for collaboration.*

**Start Date & Duration:** September 2024 for 34 months

UK | September 2024 | FA-11262860